[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-arterial-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-arterial-hemorrhage":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100573170","onyx-liquid-embolic-ide-clinical-study-100573170",false,"NCT06742801","Onyx™ Liquid Embolic IDE Clinical Study","PELE IDE Clinical Study, Peripheral Onyx™ Liquid Embolic Safety and Effectiveness of The Onyx™ LES for Embolization of Arterial Hemorrhage in the Peripheral Vasculature","Inclusion Criteria:\n\n1. Patient is ≥ 22 years old.\n2. Active arterial bleeding in the peripheral vasculature confirmed by radiologic and\u002For endoscopic imaging and deemed suitable for embolization treatment by the investigator.\n\n   In this study, peripheral vasculature is defined as outside the brain and heart.\n3. Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.\n4. Life expectancy of \\>30 days, in the opinion of the investigator at the time of enrollment.\n5. Target treatment area is free from prior embolization treatment.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding.\n2. Symptoms of active infection.\n3. Patient is known to be participating in the study of an investigational drug, biologic, or device.\n4. Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.\n5. Known allergy to components of Onyx™.\n6. Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.\n7. More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.","ALL","22 Years",{"count":19,"type":20},119,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.",[26,27,28,29,30],"Peripheral Arterial Hemorrhage","Trauma","GI Bleed","Ulcer","Hemorrhage",[26,32],"Embolization treatment","RECRUITING","2026-06-02",{"date":36,"type":37},"2026-06-03","ACTUAL",{"date":39,"type":37},"2025-05-09",{"date":41,"type":20},"2027-05",{"name":43,"class":44},"Medtronic Endovascular","INDUSTRY",18,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100604968","the-clinical-application-of-peripheral-embolization-coil-systems-in-arteriovenous-embolization-within-the-peripheral-vasculature-100604968","NCT07156409","The Clinical Application of Peripheral Embolization Coil Systems in Arteriovenous Embolization Within the Peripheral Vasculature","A Prospective, Multicenter, Single-Arm Target Value Study Evaluating the Safety and Effectiveness of a Peripheral Embolization Coil System for the Treatment of Arteriovenous Embolization in the Peripheral Vasculature in a Real-World Setting","Inclusion Criteria:\n\n1. Aged 18 to 75 years (inclusive), regardless of gender;\n2. Patients diagnosed preoperatively via imaging (including but not limited to ultrasound, CTA, MRA, DSA, etc.) with peripheral arteriovenous conditions requiring embolization therapy;\n3. The visually estimated normal reference diameter of the target vessel is ≥ 3mm;\n4. Patients or their legally authorized representatives are capable of understanding the study objectives, voluntarily participating in this study, providing signed informed consent, and able to comply with follow-up.\n\nExclusion Criteria:\n\n1. The target vessel requires the concurrent use of other embolic materials (e.g., Gelfoam, embolic microspheres, liquid embolic agents, etc.);\n2. Known definite history of allergy to platinum, tungsten metals, and\u002For any component of the investigational product;\n3. Subjects with pre-existing severe cardiac, hepatic, renal, respiratory diseases, or coagulation disorders who are unsuitable for anesthesia or endovascular surgical treatment;\n4. High-flow arteriovenous fistulas that may cause migration of the embolic material;\n5. The target aneurysm is a blister aneurysm, dissecting aneurysm, mycotic (infectious) aneurysm, ruptured aneurysm, or aneurysm caused by connective tissue diseases;\n6. Severe vascular stenosis or tortuosity, or anatomical anomalies where it is anticipated that the device will be difficult to navigate to the lesion site, or other uncommon anatomies that may interfere with device use;\n7. The target vessel has undergone any previous embolization therapy or surgical intervention, or has recurrent disease;\n8. Definite allergy, resistance, or contraindication to antiplatelet drugs, anticoagulants, contrast media, and\u002For anesthetics;\n9. Females who are pregnant, breastfeeding, or planning to become pregnant within 6 months; males planning for parenthood within the next 6 months;\n10. Subjects currently participating in other drug or device clinical trials who have not reached the trial endpoint;\n11. Investigators deem the subject unsuitable for participation in this study.","18 Years","75 Years",{"count":56,"type":20},139,[23],"Evaluation of the Safety and Effectiveness of the Peripheral Embolization Coil System Manufactured by Suzhou Zhongtian Medical Instruments Co., Ltd. for the Treatment of Arteriovenous Embolization in the Peripheral Vasculature in a Real-World Setting",[26,60,61,62],"Arteriovenous Malformation","Arteriovenous Fistula","Peripheral Aneurysm","NOT_YET_RECRUITING","2025-09-04",{"date":66,"type":37},"2025-09-05",{"date":68,"type":20},"2025-09",{"date":70,"type":20},"2026-12",{"name":72,"class":44},"Suzhou Zenith Vascular Scitech Co., Ltd."]